Articles

Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib. Read More ›

Researchers have identified a CDK4/6 inhibitor–sensitive E2F4 gene expression signature in estrogen receptor (ER)-positive breast cancers resistant to aromatase inhibitors that can potentially identify patients with ER-positive breast cancer who are candidates for adjuvant therapy with CDK4/6 inhibitors in combination with antiestrogens. Read More ›

Abemaciclib, but not ribociclib or palbociclib, exhibits inhibition of CDK4/6 plus kinases other than CDK4/6, and induces cell death rather than cytostasis, which may be therapeutically advantageous in patients with hormone receptor‒positive breast cancer that is generally resistant to CDK4/6 inhibitors. Read More ›

Triplet therapy consisting of an mTOR inhibitor, a CDK4/6 inhibitor, and an estrogen receptor (ER) antagonist such as fulvestrant may be optimal in treating hormone receptor–positive metastatic breast cancer, especially in the setting of CDK4/6-resistant tumors. Read More ›

A comparison of the relative efficacy of combination hormone therapies in hormone receptor‒ positive/HER2-negative metastatic breast cancer (MBC) suggests that everolimus/exemestane may be the most effective treatment option available. Read More ›

Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. Read More ›

Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer. Read More ›

The phase 1b trial of the insulin-like growth factor ligand-neutralizing antibody xentuzumab and the CDK4/6 inhibitor abemaciclib, plus endocrine therapy, is designed to evaluate safety, tolerability, and preliminary efficacy in patients with locally advanced or metastatic hormone receptor (HR)-positive/HER2-negative breast cancer. Read More ›

Although there are currently no biomarkers to guide the use of CDK4/6 inhibitors for estrogen receptor (ER)-positive breast cancer, markers of mismatch repair dysregulation could identify patients in whom CDK4/6 inhibition may prevent disease recurrence most effectively. Read More ›

An underlying mechanism of combined endocrine therapy and CDK4/6 inhibitor resistance in hormone receptor–positive breast cancer is senescent escape, and 2 novel therapeutic strategies have been identified for this disease, including MDM2 inhibition and CDK2 activation. Read More ›